Investigational drug · Phase 3
Batoclimab
Also called: IMVT-1401
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease, Graves Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
7
Any phase or sponsor naming "Batoclimab"
First trial start
2022
Nov 23, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Batoclimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease
- Graves Disease
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Batoclimab" as an intervention, largest first.
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia GravisPivotal-lookingTerminated
Immunovant Sciences GmbHIndustry
NCT05403541 · 233 participants · Start Jun 27, 2022 · Primary completion Jan 10, 2025
Drug: Batoclimab 680 mg SC weekly; Batoclimab 340 mg SC weekly and 2 more · For: Generalized Myasthenia Gravis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Carlsbad, California · 93 sites in all
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseasePivotal-lookingCompleted
Immunovant Sciences GmbHIndustry
NCT05517421 · 114 participants · Start Nov 23, 2022 · Primary completion Nov 2, 2025
Drug: Batoclimab; Placebo · For: Thyroid Eye Disease
Sites: Beverly Hills, California; Carlsbad, California; Los Angeles, California · 93 sites in all
- Extension Study to Assess Batoclimab in Participants With Thyroid Eye DiseasePivotal-lookingTerminated
Immunovant Sciences GmbHIndustry
NCT05517447 · 109 participants · Start Nov 6, 2022 · Primary completion Apr 2, 2026
Drug: Batoclimab · For: Thyroid Eye Disease
Sites: Glendora, California; Aurora, Colorado; Livonia, Michigan · 55 sites in all
Immunovant Sciences GmbHIndustry
NCT05581199 · 94 participants · Start Dec 15, 2022 · Primary completion Jul 20, 2026
Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly; Batoclimab 340 mg SC weekly and 1 more · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 98 sites in all
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseasePivotal-lookingCompleted
Immunovant Sciences GmbHIndustry
NCT05524571 · 86 participants · Start Jan 5, 2023 · Primary completion Feb 3, 2026
Drug: Batoclimab; Placebo · For: Thyroid Eye Disease
Sites: Pasadena, California; San Francisco, California; Torrance, California · 45 sites in all
Immunovant Sciences GmbHIndustry
NCT05907668 · 32 participants · Start May 15, 2023 · Primary completion Jul 25, 2025
Drug: IMVT-1401 (batoclimab) · For: Graves Disease
Sites: Mainz, Germany
Immunovant Sciences GmbHIndustry
NCT07188844 · 26 participants · Start Aug 28, 2025 · Primary completion Jul 16, 2026
Drug: Batoclimab · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: New Haven, Connecticut; Ormond Beach, Florida; Nicholasville, Kentucky · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rapid Serum IgG Reduction as a Potential Indicator of Short-Term Clinical Improvement in AChR-Ab-Positive Generalized Myasthenia Gravis: A Post Hoc Analysis of a Phase III Batoclimab Trial.
Li Z, Ke Q, Xi J, et al. · Neurol Ther 2026
- Emerging Therapeutic Strategies for Graves' Disease: Current Advances and Future Perspectives.
Antonelli A, Fallahi P · Curr Pharm Des 2026
- New horizons for autoimmune hyperthyroidism with FcRn blockers.
Middleton F, Abraham P · Curr Opin Endocrinol Diabetes Obes 2026
- Regimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial design.
Roy SS, Padhy BM, Anil A, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- How to manage thyroid eye disease: recent advances - a narrative review.
Markantes GK, Effraimidis G, Karapanou O, et al. · Drugs Context 2026
- Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Waseem MH, Abideen ZU, Iqbal M, et al. · Brain Behav 2026
Also in development for Thyroid Eye Disease
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- KHN939Phase 32 trials
Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease
- linsitinibPhase 32 trials
Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
- lonigutamabPhase 21 trial
ACELYRIN Inc. · Thyroid Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.